Factors Related to Omalizumab Drug Survival and Treatment Responses in Chronic Urticaria.

This study aimed to evaluate factors affecting drug survival and treatment response in patients with chronic urticaria treated with omalizumab in clinical practice.This study included 386 patients with chronic urticaria. Demographic characteristics, clinical features, laboratory parameters, and omalizumab treatment data were analyzed retrospectively. The 7-day urticaria activity score (UAS7) and urticaria control test (UCT) were used to assess disease severity and treatment responses.Well-controlled disease (UAS7 ≤6) was achieved in 59.3% of patients at a median of 2 months. Complete response was significantly higher in patients treated with omalizumab for ≥12 months (p < 0.001). Family history of asthma (p = 0.01) was less frequent, and disease duration (p = 0.041) was shorter in patients with well-controlled disease. Total treatment duration was longer in patients with relapse (p < 0.001) and serum Helicobacter pylori IgA positivity (p = 0.029).Treatment response is better in patients treated with omalizumab for ≥12 months. However, prolonged treatment does not prevent relapse. Our findings suggest that continuous or intermittent therapy is an appropriate alternative treatment option in patients with severe chronic urticaria; however, continuous therapy can be preferred to maintain the patient's quality of life.© 2022 S. Karger AG, Basel.

Citation

Eda Hasal, Emel Bulbul Baskan, Serkan Yazici, Kenan Aydogan, Hayriye Saricaoglu. Factors Related to Omalizumab Drug Survival and Treatment Responses in Chronic Urticaria. International archives of allergy and immunology. 2022 Aug 29:1-11

PMID: 36037806

search → result